Hemostemix Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
243.70
3,305.50
506.60
34.80
5,213.40
1,471
Total Accounts Receivable
-
250.30
18.90
16.00
27.10
103
Other Current Assets
-
188.90
79.70
74.40
62.00
88.20
Total Current Assets
243.70
3,744.70
605.20
125.30
5,302.50
1,662.30
Net Property, Plant & Equipment
-
152.40
138.90
101.80
-
-
Intangible Assets
-
0.00
0.00
0.00
0.00
-
Other Assets
33.60
44.20
52.80
-
-
-
Total Assets
277.30
3,941.30
796.80
227.10
5,302.50
1,662.30
ST Debt & Current Portion LT Debt
-
-
-
1,045.80
-
Accounts Payable
21.90
-
-
-
-
Income Tax Payable
-
34.00
7.20
4.80
-
Other Current Liabilities
8.50
517.70
615.50
2,326.10
464.80
Total Current Liabilities
30.40
551.70
622.70
3,376.70
464.80
Long-Term Debt
-
-
-
343.20
-
Other Liabilities
-
-
-
41.70
-
Total Liabilities
30.40
551.70
622.70
3,761.50
464.80
Common Equity (Total)
247.00
3,389.60
174.10
3,534.40
4,837.70
Total Shareholders' Equity
247.00
3,389.60
174.10
3,534.40
4,837.70
Total Equity
247.00
3,389.60
174.10
3,534.40
4,837.70
Liabilities & Shareholders' Equity
277.30
3,941.30
796.80
227.10
5,302.50

About Hemostemix

View Profile
Address
300-5th Avenue SW
Calgary Alberta T2P 3C4
Canada
Employees -
Website http://www.hemostemix.com
Updated 07/08/2019
Hemostemix, Inc. is a clinical stage biotechnology company, which engages in the development, manufacture, and commercialization of blood-derived cell therapies to treat ischemic diseases. It focuses its operation in North America. The company was founded on March 26, 2012 and is headquartered in Calgary, Canada.